$DYN
Dyne Therapeutics Inc

2023 Q2 Form 10-Q Financial Statement

#000095017023020839 Filed on May 11, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $7.606M $7.928M $7.547M
YoY Change 24.87% 5.05% 15.93%
% of Gross Profit
Research & Development $59.13M $37.54M $28.24M
YoY Change 26.71% 32.94% 51.6%
% of Gross Profit
Depreciation & Amortization $400.0K $400.0K $400.0K
YoY Change -20.0% 0.0% 100.0%
% of Gross Profit
Operating Expenses $66.74M $45.46M $35.78M
YoY Change 26.5% 27.05% 42.37%
Operating Profit -$66.74M -$45.46M -$35.78M
YoY Change 26.5% 27.05% 42.37%
Interest Expense $2.207M $1.493M $230.0K
YoY Change 400.45% 549.13% 35.29%
% of Operating Profit
Other Income/Expense, Net $1.834M $1.277M $200.0K
YoY Change 306.65% 538.5% 20.48%
Pretax Income -$64.90M -$44.19M -$35.58M
YoY Change 24.09% 24.18% 42.5%
Income Tax
% Of Pretax Income
Net Earnings -$64.90M -$44.19M -$35.58M
YoY Change 24.09% 24.18% 42.51%
Net Earnings / Revenue
Basic Earnings Per Share -$1.08 -$0.78 -$0.69
Diluted Earnings Per Share -$1.08 -$0.78 -$689.6K
COMMON SHARES
Basic Shares Outstanding 58.31M 56.34M 51.64M
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $207.7M $238.2M $323.2M
YoY Change -28.82% -26.28% -33.11%
Cash & Equivalents $167.6M $181.1M $148.0M
Short-Term Investments $40.13M $57.10M $175.2M
Other Short-Term Assets $5.440M $11.00M $21.30M
YoY Change -10.76% -48.34% 432.5%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $213.2M $249.2M $344.5M
YoY Change -28.45% -27.65% -29.28%
LONG-TERM ASSETS
Property, Plant & Equipment $5.359M $5.569M $5.619M
YoY Change -2.26% -0.89% 216.21%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.323M $2.321M $2.313M
YoY Change 0.35% 0.35% 0.57%
Total Long-Term Assets $38.25M $39.43M $43.31M
YoY Change -9.13% -8.97% 833.05%
TOTAL ASSETS
Total Short-Term Assets $213.2M $249.2M $344.5M
Total Long-Term Assets $38.25M $39.43M $43.31M
Total Assets $251.4M $288.6M $387.8M
YoY Change -26.06% -25.56% -21.14%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.724M $8.770M $5.188M
YoY Change -60.93% 69.04% -9.93%
Accrued Expenses $17.50M $12.82M $18.05M
YoY Change -6.18% -28.99% 134.4%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $20.22M $21.59M $23.24M
YoY Change -21.08% -7.1% 72.13%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $24.32M $25.12M $28.07M
YoY Change -11.05% -10.5%
Total Long-Term Liabilities $24.32M $25.12M $28.07M
YoY Change -11.05% -10.5%
TOTAL LIABILITIES
Total Short-Term Liabilities $20.22M $21.59M $23.24M
Total Long-Term Liabilities $24.32M $25.12M $28.07M
Total Liabilities $44.54M $46.71M $51.30M
YoY Change -15.9% -8.96% 281.43%
SHAREHOLDERS EQUITY
Retained Earnings -$505.7M -$440.8M -$264.1M
YoY Change 59.84% 66.92% 153.53%
Common Stock $6.000K $6.000K $6.000K
YoY Change 0.0% 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $206.9M $241.9M $336.5M
YoY Change
Total Liabilities & Shareholders Equity $251.4M $288.6M $387.8M
YoY Change -26.06% -25.56% -21.14%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$64.90M -$44.19M -$35.58M
YoY Change 24.09% 24.18% 42.51%
Depreciation, Depletion And Amortization $400.0K $400.0K $400.0K
YoY Change -20.0% 0.0% 100.0%
Cash From Operating Activities -$55.64M -$46.91M -$50.74M
YoY Change 80.02% -7.55% 175.86%
INVESTING ACTIVITIES
Capital Expenditures $250.0K $230.0K $1.401M
YoY Change -195.79% -83.58% 15466.67%
Acquisitions
YoY Change
Other Investing Activities $17.48M $27.29M -$735.0K
YoY Change -6.53% -3813.2% -99.43%
Cash From Investing Activities $17.23M $27.06M -$2.136M
YoY Change -6.57% -1366.95% -98.34%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 24.91M 28.82M 18.00K
YoY Change 25057.58% 159983.33% -99.99%
NET CHANGE
Cash From Operating Activities -55.64M -46.91M -50.74M
Cash From Investing Activities 17.23M 27.06M -2.136M
Cash From Financing Activities 24.91M 28.82M 18.00K
Net Change In Cash -13.50M 8.969M -52.86M
YoY Change 9.19% -116.97% -604.26%
FREE CASH FLOW
Cash From Operating Activities -$55.64M -$46.91M -$50.74M
Capital Expenditures $250.0K $230.0K $1.401M
Free Cash Flow -$55.89M -$47.14M -$52.14M
YoY Change 82.37% -9.59% 183.34%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001818794
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-39509
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
Dyne Therapeutics, Inc.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
36-4883909
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
1560 Trapelo Road
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Waltham
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02451
CY2023Q1 dei City Area Code
CityAreaCode
781
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
786-8230
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
CY2023Q1 dei Trading Symbol
TradingSymbol
DYN
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
58310703
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
181114000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
172147000
CY2023Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
57097000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
83865000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
11003000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9582000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
249214000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
265594000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5569000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5945000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
31538000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
32467000
CY2023Q1 dyn Restricted Cash And Other Assets Noncurrent
RestrictedCashAndOtherAssetsNoncurrent
2321000
CY2022Q4 dyn Restricted Cash And Other Assets Noncurrent
RestrictedCashAndOtherAssetsNoncurrent
2319000
CY2023Q1 us-gaap Assets
Assets
288642000
CY2022Q4 us-gaap Assets
Assets
306325000
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
8770000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5259000
CY2023Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
8173000
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
18219000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4644000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4610000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
21587000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
28088000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
25120000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
25873000
CY2023Q1 us-gaap Liabilities
Liabilities
46707000
CY2022Q4 us-gaap Liabilities
Liabilities
53961000
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
58305480
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
58305480
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
55636505
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
55636505
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
6000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
6000
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
682892000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
649502000
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-203000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-571000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-440760000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-396573000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
241935000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
252364000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
288642000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
306325000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
37536000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
28236000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7928000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7547000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
45464000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
35783000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-45464000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-35783000
CY2023Q1 us-gaap Interest Income Other
InterestIncomeOther
1493000
CY2022Q1 us-gaap Interest Income Other
InterestIncomeOther
230000
CY2023Q1 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-216000
CY2022Q1 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-30000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1277000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
200000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-44187000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-35583000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.78
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.78
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.69
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.69
CY2023Q1 us-gaap Weighted Average Limited Partnership Units Outstanding Diluted
WeightedAverageLimitedPartnershipUnitsOutstandingDiluted
56325864
CY2023Q1 us-gaap Weighted Average Limited Partnership Units Outstanding
WeightedAverageLimitedPartnershipUnitsOutstanding
56325864
CY2022Q1 us-gaap Weighted Average Limited Partnership Units Outstanding Diluted
WeightedAverageLimitedPartnershipUnitsOutstandingDiluted
51601444
CY2022Q1 us-gaap Weighted Average Limited Partnership Units Outstanding
WeightedAverageLimitedPartnershipUnitsOutstanding
51601444
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-44187000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-35583000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
368000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-661000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-43819000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-36244000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
252364000
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
28186000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
587000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4617000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
368000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-44187000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
241935000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
368197000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
18000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4488000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-661000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-35583000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
336459000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-44187000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-35583000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
4617000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
4488000
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
412000
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
425000
CY2023Q1 dyn Non Cash Lease Expense
NonCashLeaseExpense
211000
CY2022Q1 dyn Non Cash Lease Expense
NonCashLeaseExpense
1041000
CY2023Q1 dyn Amortization Accretion Of Premium Discount On Marketable Securities
AmortizationAccretionOfPremiumDiscountOnMarketableSecurities
-181000
CY2022Q1 dyn Amortization Accretion Of Premium Discount On Marketable Securities
AmortizationAccretionOfPremiumDiscountOnMarketableSecurities
605000
CY2023Q1 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
-23000
CY2022Q1 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
-30000
CY2023Q1 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-118000
CY2022Q1 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1390000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
15477000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
-6531000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
-6268000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-46908000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-50739000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
230000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1401000
CY2023Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
16687000
CY2022Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
55327000
CY2023Q1 dyn Maturities Of Marketable Securities
MaturitiesOfMarketableSecurities
42150000
CY2022Q1 dyn Maturities Of Marketable Securities
MaturitiesOfMarketableSecurities
52077000
CY2023Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
1829000
CY2022Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
2515000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
27062000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2136000
CY2023Q1 dyn Proceeds From Issuance Follow On Public Offering
ProceedsFromIssuanceFollowOnPublicOffering
28228000
CY2022Q1 dyn Proceeds From Issuance Follow On Public Offering
ProceedsFromIssuanceFollowOnPublicOffering
0
CY2023Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
587000
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
18000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
28815000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
18000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
8969000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-52857000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
174466000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
203519000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
183435000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
150662000
CY2023Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
39000
CY2022Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
167000
CY2023Q1 dyn Public Offering Costs Included In Accounts Payable Or Accrued Expenses
PublicOfferingCostsIncludedInAccountsPayableOrAccruedExpenses
42000
CY2022Q1 dyn Public Offering Costs Included In Accounts Payable Or Accrued Expenses
PublicOfferingCostsIncludedInAccountsPayableOrAccruedExpenses
0
CY2023Q1 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2017-12-01
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
572000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
83865000
CY2023Q1 dyn Fair Value Assets Transfers Amount
FairValueAssetsTransfersAmount
0
CY2023Q1 us-gaap Dividends Common Stock Paidinkind
DividendsCommonStockPaidinkind
10878916000
CY2022Q1 us-gaap Dividends Common Stock Paidinkind
DividendsCommonStockPaidinkind
8992216000
CY2023Q1 dyn Cash And Cash Equivalents Maturity Period
CashAndCashEquivalentsMaturityPeriod
P90D
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
181114000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
172147000
CY2023Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2321000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2319000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
183435000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
174466000
CY2023Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
57300000
CY2023Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
10000
CY2023Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
213000
CY2023Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
57097000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
84436000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000
CY2022Q4 dyn Fair Value Assets Transfers Amount
FairValueAssetsTransfersAmount
0
CY2023Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
57046000
CY2023Q1 dyn Available For Sale Debt Securities Maturity After Year One Through Two Years Fair Value
AvailableForSaleDebtSecuritiesMaturityAfterYearOneThroughTwoYearsFairValue
51000
CY2023Q1 dyn Available For Sale Debt Securities Maturity After Year Two Years Fair Value
AvailableForSaleDebtSecuritiesMaturityAfterYearTwoYearsFairValue
0
CY2023Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
57097000
CY2023Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9596000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9574000
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4027000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3629000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5569000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5945000
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
400000
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
400000
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
13.00
CY2023Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
232292
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.53
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1736000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5935000
CY2023Q1 dyn Accrued Consulting Services Current
AccruedConsultingServicesCurrent
679000
CY2022Q4 dyn Accrued Consulting Services Current
AccruedConsultingServicesCurrent
776000
CY2023Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
711000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
410000
CY2023Q1 dyn Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
5047000
CY2022Q4 dyn Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
11097000
CY2023Q1 dyn Accrued Facility Costs Current
AccruedFacilityCostsCurrent
0
CY2022Q4 dyn Accrued Facility Costs Current
AccruedFacilityCostsCurrent
1000
CY2023Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
8173000
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
18219000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.67
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.73
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0342
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0422
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0147
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0244
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9381429
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.59
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y2M12D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
34879000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
207500
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
76062
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
11.06
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9280575
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.83
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
32227000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4367617
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
8.91
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y4M24D
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
20449000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
9280575
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
9.83
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
32227000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
2200000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
100000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.22
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.75
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4617000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4488000

Files In Submission

Name View Source Status
dyn-20230331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
0000950170-23-020839-index-headers.html Edgar Link pending
0000950170-23-020839-index.html Edgar Link pending
0000950170-23-020839.txt Edgar Link pending
0000950170-23-020839-xbrl.zip Edgar Link pending
dyn-20230331.htm Edgar Link pending
dyn-20230331.xsd Edgar Link pending
dyn-ex31_1.htm Edgar Link pending
dyn-ex31_2.htm Edgar Link pending
dyn-ex32_1.htm Edgar Link pending
dyn-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
dyn-20230331_def.xml Edgar Link unprocessable
dyn-20230331_cal.xml Edgar Link unprocessable
dyn-20230331_lab.xml Edgar Link unprocessable
dyn-20230331_htm.xml Edgar Link completed
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending